TEX CORE developed compounds are designed to be tumor localizing, well-tolerated, MRI-detectable and efficacious in multiple solid tumors, including cancer cells that fail to respond to current therapies. An innovative texaphyrin technology platform, TEX CORE conjugates with new and pre-existing oncology therapies to create novel compounds that are delivered directly to tumor cells with minimal side effects.
The innovative TEX CORE platform facilitates the chemical conjugation of oncology therapies with texaphyrin, creating novel oncology compounds that are delivered directly to tumor cells with minimal side effects.
86% of patients experience side effects from traditional chemotherapy treatments and 27% of those side effects are potentially life threatening.
TEX CORE developed compounds are designed to be tumor localizing, well-tolerated, MRI-detectable and efficacious in multiple solid tumors, including cancer cells that fail to respond to current therapies.
OxaliTEX is the conjugation of texaphyrin and a platinum (IV) prodrug. This allows OxaliTEX to localize to ovarian cancer and overcome drug resistance.
AuraTEX is a novel gold-based therapy that can both eradicate cancer and stimulate an anti-cancer immune response. AuraTEX participates in 2 key anticancer mechanisms of action that occur sequentially. First, after AuraTEX enters the cancer, it forces the formation of free radicals inside the tumor. This elevation in free radicals damages the cancer’s mitochondria and endoplasmic reticulum. After this mechanism, the damage forces the release of 3 key biomarkers from the cancer. These biomarkers are subsequently identified by the immune system. Once this happens, killer T Cells are formed and also begin fighting the cancer.
InnovoTEX licensed the IP (consisting of more than 40 patents and patent applications) to the innovative anticancer drug platform, TEX CORE, from the University of Texas at Austin in 2022. The first TEX CORE oncology compound to be developed is OxaliTEX, a conjugation of oxaliplatin and texaphryn, which localizes to solid tumors including ovarian, lung and colorectal cancers.
Preliminary research evidence has been reported in multiple peer reviewed scientific journals including Proceedings of the National Academy of Sciences of the United States of America, Journal of the American Chemical Society, Chem, Chemical Science, Chemical Communications, Medicinal Chemical Communications, Cancer Research and Chemical Society Reviews.
Current platinum-based anticancer drugs have limitations. Almost half of all chemotherapy patients are treated with platinum-based drugs such as cisplatin, carboplatin and oxaliplatin. While these drugs kill cancer cells, they are also toxic to healthy cells, resulting in debilitating side effects. Over time, traditional chemotherapy drugs can become ineffective as cancer cells develop drug resistance to platinum-based chemotherapies.
OxaliTEX is currently in the preclinical stage. Early demonstration batches and clinical-grade OxaliTEX are currently being manufactured. Following this, we will evaluate the safety of OxaliTEX per regulatory standards.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.